Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

This publication has 27 references indexed in Scilit:

• Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
  Journal of Clinical Oncology, 2009
• A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
  Journal of Urology, 2008
• Determinants of Change in Prostate-Specific Antigen Over Time and Its Association With Recurrence After External Beam Radiation Therapy for Prostate Cancer in Five Large Cohorts
  International Journal of Radiation Oncology*Biology*Physics, 2008
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
  Nature Reviews Cancer, 2008
• Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
  Journal of Clinical Oncology, 2008
• Prostate cancer‐specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high‐risk factors
  Cancer, 2007
• Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
  Nature Clinical Practice Oncology, 2006
• Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)
  Journal of Clinical Oncology, 2006
• Is preoperative serum prostate‐specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
  BJU International, 2005
• Phase II Study of Abarelix Depot for Androgen Independent Prostate Cancer Progression During Gonadotropin-Releasing Hormone Agonist Therapy
  Journal of Urology, 2003